Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Verrica Pharmaceuticals Inc

VRCA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$5.30

▼ -1.12%

Market Cap $91.05M · Vol 3.28K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$91.05M

Micro Cap

Div Yield

N/A

EPS Growth

-14.68%

YoY

RSI (14)

58.87

Momentum

Beta

1.59

vs Market

52W High

$9.81

45.95% below

52W Low

$3.28

61.59% above

Volume

3.28K

Avg 26.40K

P/B

5.77

Price-to-book

ROE

N/A

Return on equity

Free Float

51.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Verrica Pharmaceuticals Inc (VRCA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VRCA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.85%

-2.03%

-13.82%

-0.56%

YTD

-36.22%

+2.71%

-87.82%

-96.20%

Financials & Valuation

TTM · Annual

Total Revenue	$35.58M
Net Income	$-17,886,000.00
Revenue Growth (YoY)	-53.85%
Gross Margin	90.33%
Operating Margin	-33.56%
Net Profit Margin	-50.27%
ROE	N/A
ROA · ROIC	-35.33% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.49
P/B	5.77
P/FCF	N/A
EPS Growth	-14.68%
Outstanding Shares	17.18M

Technical Indicators

50-Day SMA	$5.47
200-Day SMA	$6.26
RSI (14)	58.87
Beta	1.59
52-Week High	$9.81
52-Week Low	$3.28

Volume Today	3.28K
Avg Daily Volume (30D)	26.40K
Relative Volume	0.12x
Volatility (10D)	67.33
Volatility (30D)	58.30
Free Float	51.00%

Analyst Consensus

BUY

Current Price $5.30

Mean Target $13.83

52W Low$3.28 52W High$9.81

Current

Target

$3.28 $9.81

Current Analyst target

+161.01% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00L03BZ24

ISINUS92511W2070

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -0.88% JNJ Johnson & Johnson -1.15% ABBV Abbvie Inc -1.44% NVS Novartis AG -1.90% NOVN.S Novartis AG -1.33%

Company Profile

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).